Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 21;59(4):2200024.
doi: 10.1183/13993003.00024-2022. Print 2022 Apr.

Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosis

Tim J M Wallis  1   2 , Eyjólfur Gudmundsson  3 , Katarina Pontoppidan  4 , Nesrin Mogulkoc  5 , Recep Savaş  6 , Ömer Selim Unat  5 , Katharine Vedwan  7 , Sobana Battison  7 , Fiona J Thompson  4 , Christopher J Brereton  4   2 , Ben G Marshall  4   2 , Sophie V Fletcher  4   2 , Luca Richeldi  4   8 , Joseph Jacob  3   9 , Mark G Jones  4   2
Affiliations

Temporal progression of mediastinal lymphadenopathy in idiopathic pulmonary fibrosis

Tim J M Wallis et al. Eur Respir J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Author contributions: Conceptualisation of the study: M.G. Jones, K. Pontoppidan, T.J.M. Wallis and J. Jacob; data curation: K. Pontoppidan, E. Gudmundsson, C.J. Brereton, T.J.M. Wallis, F.J. Thompson, S. Battison, K. Vedwan, N. Mogulkoc, Ö.S. Unat and R. Savaş; radiological analysis: S. Battison, K. Vedwan and J. Jacob; formal analysis: T.J.M. Wallis, K. Pontoppidan, E. Gudmundsson and M.G. Jones; writing original draft: T.J.M. Wallis, K. Pontoppidan and M.G. Jones; manuscript review and editing: T.J.M. Wallis, K. Pontoppidan, M.G. Jones, F.J. Thompson, C.J. Brereton, S. Battison, K. Vedwan, B.G. Marshall, L. Richeldi, S.V. Fletcher, J. Jacob and E. Gudmundsson. Conflict of interest: J. Jacob reports fees from Boehringer Ingelheim, Roche, NHSX and GlaxoSmithKline, unrelated to the submitted work. L. Richeldi reports fees from Biogen, Roche, ImmuneWorks, Boehringer Ingelheim, Celegene, Nitto, FibroGen, Promedior, Pliant Therapeutics, Asahi Kasei, Tora, BMS, REspiVant and CSL Behring, unrelated to the submitted work. T.J.M. Wallis, E. Gudmundsson, K. Pontoppidan, N. Mogulkoc, Ö.S. Unat, R. Savaş, K. Vedwan, S. Battison, C.J. Brereton, F.J. Thompson, B.G. Marshall, S.V. Fletcher and M.G. Jones have no competing interests to declare.

Figures

Figure 1
Figure 1. Influence of temporal progression of mediastinal lymphadenopathy (MLN) on survival.
Figure 1A) Cox Univariable and Multivariable Regression Analyses for influence of temporal progression of MLN on survival. All multivariable models were adjusted for Age, Antifibrotic therapy (Ever taken vs. never taken), Age, and one of two measures of baseline disease severity, either forced vital capacity percent predicted (FVC% predicted) or diffusion capacity of the lung for carbon monoxide percent predicted (DLCO% predicted). HR-Hazard Ratio, 95%CI-95% Confidence interval, Progressors - MLN≥10 mm with a ≥1 mm/year increase in size of largest node, non-progressors - MLN≥10 mm with a <1 mm/year increase in nodal size or no significant MLN on either CT. *p<0.05 **p<0.01. Figure 1B and C) Kaplan-Meier cumulative survival curves from Follow-up CT (CT2) to death or censor date (years) for temporal progression of MLN stratified as Progressor vs. Non progressor. Figure 1B) Cohort 1 total n=51. Number of deaths per group; Non progressor n=15, Progressor n=12. Log rank p=0.019. Figure 1C) Cohort 2 n=92. Number of deaths per group; Non progressor n=20 Progressor n=13. Log rank p=0.060.
Figure 1
Figure 1. Influence of temporal progression of mediastinal lymphadenopathy (MLN) on survival.
Figure 1A) Cox Univariable and Multivariable Regression Analyses for influence of temporal progression of MLN on survival. All multivariable models were adjusted for Age, Antifibrotic therapy (Ever taken vs. never taken), Age, and one of two measures of baseline disease severity, either forced vital capacity percent predicted (FVC% predicted) or diffusion capacity of the lung for carbon monoxide percent predicted (DLCO% predicted). HR-Hazard Ratio, 95%CI-95% Confidence interval, Progressors - MLN≥10 mm with a ≥1 mm/year increase in size of largest node, non-progressors - MLN≥10 mm with a <1 mm/year increase in nodal size or no significant MLN on either CT. *p<0.05 **p<0.01. Figure 1B and C) Kaplan-Meier cumulative survival curves from Follow-up CT (CT2) to death or censor date (years) for temporal progression of MLN stratified as Progressor vs. Non progressor. Figure 1B) Cohort 1 total n=51. Number of deaths per group; Non progressor n=15, Progressor n=12. Log rank p=0.019. Figure 1C) Cohort 2 n=92. Number of deaths per group; Non progressor n=20 Progressor n=13. Log rank p=0.060.
See this image and copyright information in PMC

References

    1. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. The Lancet. 2017;389(10082):1941–52. - PubMed
    1. Ley B, Collard HR, Talmadge E, King J. Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine. 2011;183(4):431–40. - PubMed
    1. Drakopanagiotakis F, Wujak L, Wygrecka M, Markart P. Biomarkers in idiopathic pulmonary fibrosis. Matrix Biology. 2018;68-69:404–21. - PubMed
    1. Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine. 2018;198(5):e44–e68. - PubMed
    1. Souza CA, Muller NL, Lee KS, Johkoh T, Mitsuhiro H, Chong S. Idiopathic interstitial pneumonias: prevalence of mediastinal lymph node enlargement in 206 patients. AJR Am J Roentgenol. 2006;186(4):995–9. - PubMed

Publication types

LinkOut - more resources